Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Neurocrine Biosciences Inc. has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA ... expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired ...

Eli Lilly will spend $3 billion ... year from Nexus Pharma as part of a massive manufacturing investment drive that aims to shore up supplies of drugs like diabetes therapy Mounjaro and Zepbound ...